Orforglipron hits Phase 3 endpoint. The oral GLP-1 heads for FDA submission.

Eli Lilly announced top-line Phase 3 data for orforglipron, its small-molecule oral GLP-1 receptor agonist, in late 2025 and early 2026. ATTAIN-1 (adults with obesity) and ACHIEVE-1 (adults with type 2 diabetes) both hit their primary endpoints. ATTAIN-MAINTAIN extended the story: patients who completed the primary obesity trial and stayed on orforglipron maintained most of their weight loss through 72 weeks, while patients switched to placebo regained substantially.

The headline numbers: ~12–15% mean weight loss at the highest dose in ATTAIN-1, below tirzepatide's ~20% SURMOUNT-1 figure but broadly comparable to semaglutide's STEP-1 ~14.9%. For T2D, ACHIEVE-1 reported HbA1c reductions in the ~1.5–2.0% range at equivalent comparator points to injectable semaglutide.

Why the oral route matters even at slightly lower efficacy

Injection aversion is real and measurable. Surveys of eligible GLP-1 candidates consistently find that 20–40% of people who could benefit from the class refuse it specifically because of the injection. An oral pill expands the addressable population meaningfully even if the mean efficacy is ~5 percentage points lower than the injectable leader.

Supply-side, the oral small-molecule story is even bigger. The 2022–2025 GLP-1 shortage was fundamentally a peptide-manufacturing bottleneck. Orforglipron is a small molecule — it can be made at drug-industry scale using standard organic chemistry, not the specialized peptide-synthesis equipment that constrained Novo and Lilly's ability to keep up with demand. A peptide-free GLP-1 supply chain doesn't bottleneck the same way.

The pipeline is getting crowded

Orforglipron won't be alone. Pfizer's danuglipron is also an oral small-molecule GLP-1, though Pfizer discontinued the twice-daily formulation in 2023 after tolerability issues and is pursuing a once-daily version. Roche has aleniglipron. Eventually, the oral GLP-1 market will probably look like the injectable market — multiple brands, modest differentiation, price competition.

What's still not settled

Cardiovascular outcomes data for orforglipron doesn't exist yet. Semaglutide has the 2023 SELECT trial establishing MACE reduction in obesity; tirzepatide's SURPASS-CVOT is ongoing. Orforglipron's cardiovascular outcomes program is early, and cardiologists will treat the injectable option with better CV data as the default for patients with established CV disease until parity is established.

Also unresolved: real-world tolerability at effective dose, insurance coverage (new drugs take 12–24 months to reach broad formulary), and pricing. Lilly hasn't disclosed where they'll price orforglipron relative to Zepbound.